tcsc0776 SLx-2119

SLx-2119 is a selective inhibitor of ROCK2 with IC₅₀ of 105 nM, more than 200 fold selecivity over ROCK1 (IC₅₀=24 μM).

IC50 & Target: IC50: 105 nM (ROCK2)^[1]

In Vitro: SLx-2119 (40 µM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASMC. The microarray hybridized with aRNA from HMVEC treated with SLx-2119, shows a 5-times higher background than the other arrays^[1].

In Vivo: KD025 (100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. KD025 is at least as efficacious in aged, diabetic or female mice, as in normal adult males^[2].